CONFIRM: CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Sponsor

University of Southampton (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT03063450

Collaborator

Bristol-Myers Squibb (Industry)

332

Enrollment

Locations

Arms

62.1

Anticipated Duration (Months)

13.8

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The UK has the highest incidence of mesothelioma. The incidence has risen by 497% since the late 1970's and is increasing worldwide due to continued mining and use of asbestos. For patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin, there is currently no standard treatment, making this an urgent unmet need. Recent trials in this area have not found an effective treatment that improves overall survival.

Following a debate in the House of Lords, a national survey assessing the research priorities in mesothelioma found that 'exploiting the potential of immunotherapy' was a top priority. This trial was designed in response to that survey. It uses the immunotherapy agent nivolumab which blocks programmed cell death 1 (PD-1) receptor on activated T-cells (a type of white blood cell forming part of the immune system). Early research has found a dependency of mesothelioma on the PD-1 checkpoint. By attaching to PD-1, nivolumab blocks its action (checkpoint inhibition), preventing it from turning off the T-cell, and therefore allowing the immune system to work. PD-1 checkpoint inhibition has revolutionised the treatment of melanoma and it is hoped to be as effective in mesothelioma.

This trial is a randomised, double blind placebo controlled trial of patients with mesothelioma who are second or third relapse following a platinum based chemotherapy treatment. Patients will be randomised in a 2:1 ratio (nivolumab: placebo).

336 patients will be recruited from 25 UK centres with the last patient having a minimum of 6 months follow up. All patients will be on treatment for 12 months unless they progress or withdrawal prior to this.

Condition or Disease	Intervention/Treatment	Phase
Mesothelioma	Drug: Nivolumab Other: Placebo	Phase 3

Study Design

Study Type:

Interventional

Actual Enrollment :

332 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma

Actual Study Start Date :

Mar 28, 2017

Anticipated Primary Completion Date :

Jun 1, 2022

Anticipated Study Completion Date :

Jun 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Nivolumab Nivolumab 240mg flat dose Q2W over 30 minutes IV until disease progression, to a maximum of 12 months	Drug: Nivolumab Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle Other Names: Opdivo
Placebo Comparator: Placebo Sterile 0.9% sodium chloride Q2W over 30 minutes IV until disease progression, to a maximum of 12 months	Other: Placebo Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle

Arm

Intervention/Treatment

Experimental: Nivolumab

Nivolumab 240mg flat dose Q2W over 30 minutes IV until disease progression, to a maximum of 12 months

Drug: Nivolumab

Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle

Other Names:

Opdivo

Placebo Comparator: Placebo

Sterile 0.9% sodium chloride Q2W over 30 minutes IV until disease progression, to a maximum of 12 months

Other: Placebo

Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle

Outcome Measures

Primary Outcome Measures

Overall survival [Time from randomisation to date of death from any cause, assessed up to 51 months]
Progression free survival (modified RECIST or RECIST 1.1) [Time from randomisation to progression, assessed up to 51 months]
Length of time patients are free from disease through study completion

Secondary Outcome Measures

Overall response rate (modified RECIST or RECIST 1.1) [Time from randomisation to progression through study completion, assessed up to 51 months]
Response of disease to treatment
Quality of life (EQ-5D-5L) [At baseline, after cycles 3 and 6 (each cycle is 14 days) and 1, 6 and 12 months post progression/treatment discontinuation.]
Toxicity (CTCAE V4.03) [At baseline, after each treatment cycle (each cycle is 14 days) and each follow up visit. Up to 30 days post progression/treatment discontinuation.]
Cost effectiveness (Health resource use questionnaire) [Up to max. 24 months. At baseline, after cycles 3 and 6 (each cycle is 14 days) and 1, 6 and 12 months post progression/treatment discontinuation.]

Other Outcome Measures

Transnational [Samples collected at baseline and optional sample at progression (assessed up to 51 months from randomisation)]
To correlate: mutation burden with OS immunosuppressive landscape (immune checkpoint expression and infiltration of immune cell) and nivolumab efficacy

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Signed and dated a REC-approved written informed consent form in accordance with regulatory and institutional guidelines. Must be obtained before the performance of any protocol-related procedures that are not part of normal patient care.
Consent to provide tissue and blood samples for research
Must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study
Histological confirmation of mesothelioma (any subtype, pleural or peritoneal).
Must have received treatment with at least one prior line of treatment. Prior maintenance therapy (e.g. avastin) is allowed and will not count as a line of therapy. Prior lines of antineoplastic therapy, including chemotherapy, surgical resection of lesions, radiation therapy, must be completed within 14 days of receiving nivolumab
ECOG PS 0-1
Age ≥18 years
Expected survival of at least 12 weeks
Radiologically assessable disease by modified RECIST (pleural mesothelioma) or RECIST 1.1 (non-pleural mesothelioma or where measurements for mRECIST cannot be obtained).
Evidence of disease progression by CT scan
Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
Screening laboratory values must meet the following criteria within 48 hours prior to commencement of treatment:

White blood cells ≥ 2 x 10^{9/L ii) Neutrophils ≥1.5 x 10}9/L iii) Platelets ≥ 100 X10^{9/L iv) Haemoglobin ≥ 90 g/L v) Serum creatinine of ≤ 1.5 X ULN or creatinine
clearance (CrCl) > 50 mL/minute (using Cockcroft/Gault formula) vi) AST ≤ 3 X ULN vii)
ALT ≤ 3 X ULN viii) Total bilirubin ≤ 1.5 X ULN (except patients with Gilbert
Syndrome, who must have total bilirubin < 51.3 μmol/L) 2 x 10}9/L

Reproductive status

Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) at enrolment and within 24 hours prior to the start of study drug.
Women must not be breastfeeding.
WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with nivolumab plus 5 half-lives of nivolumab (5 x half-life=125 days) plus 30 days (duration of ovulatory cycle) for a total of 5 months post- treatment completion.
Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception.

Expected surivial of at least 12 weeks.

Exclusion Criteria:

Target Disease Exceptions

Patients with untreated, symptomatic CNS metastases are excluded. Participants are eligible if CNS metastases are adequately treated and participants are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to treatment assignment. In addition, participants must be either off corticosteroids, or on a stable or decreasing dose of <=10 mg daily prednisone (or equivalent) for at least 2 weeks prior to treatment.
Patients with carcinomatous meningitis are excluded.

Physical and Laboratory Test Findings

Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.

Allergies and Adverse Drug Reactions

History of severe hypersensitivity reactions to other monoclonal antibodies

Medical History and Concurrent Diseases

Patients with active, known or suspected autoimmune disease.
Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of the first dose of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.
Other active malignancy requiring concurrent intervention.
Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patient to receive protocol therapy.
All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue not resolved to Grade 1 (NCI CTCAE version 4.03) or baseline before administration of study drug.
Patients who have not recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.
Known alcohol or drug abuse.
Patients who have received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti- CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) or who have previously taken part in a randomised Bristol Myers Squibb (BMS) clinical trial for nivolumab or ipilimumab including study CA209-743 (CheckMate

or in the CCTG trial of pembrolizumab (IND.227).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ulster Hospital	Dundonald	Belfast	United Kingdom	BT16 1RH
2	East Kent Hospitals University Foundation Trust	Canterbury	Kent	United Kingdom	CT1 3NG
3	Northumbria Healthcare NHS Foundation Trust	Newcastle Upon Tyne	Northumberland	United Kingdom	NE12 8EW
4	Aberdeen Royal Infirmary	Aberdeen		United Kingdom
5	Basildon University Hospital	Basildon		United Kingdom
6	Belfast City Hospital	Belfast		United Kingdom
7	Royal Bournemouth Hospital	Bournemouth		United Kingdom
8	Addenbrooke's Hospital	Cambridge		United Kingdom
9	Velindre Cancer Centre	Cardiff		United Kingdom
10	Ninewells Hospital	Dundee		United Kingdom
11	Beatson West of Scotland Cancer Centre	Glasgow		United Kingdom
12	Harrogate District Hospital	Harrogate		United Kingdom
13	Raigmore Hospital	Inverness		United Kingdom	IV2 3UJ
14	University Hospitals Morecambe Bay	Lancaster		United Kingdom
15	Leicester Royal Infirmary	Leicester		United Kingdom
16	Barts Cancer Institute	London		United Kingdom
17	University College London Hospitals NHS Foundation Trust	London		United Kingdom
18	Wythenshawe Hospital	Manchester		United Kingdom
19	Mount Vernon Cancer Centre	Northwood		United Kingdom
20	Churchill Hopsital	Oxford		United Kingdom
21	Southampton General Hospital	Southampton		United Kingdom
22	Southend Hospital	Southend-on-Sea		United Kingdom
23	Lister Hospital	Stevenage		United Kingdom
24	Musgrove Park Hospital	Taunton		United Kingdom

Sponsors and Collaborators

University of Southampton
Bristol-Myers Squibb

Investigators

Principal Investigator: Dean Fennell, University of Leicester
Principal Investigator: Gareth Griffiths, Southampton Clinical Trials Unit, University of Southampton